To compare the efficacy and safety of short-course intravenous levofloxacin (LVFX) 750 mg with a conventional intravenous/oral regimen of LVFX 500 mg in patients from China with complicated urinary tract infections (cUTIs) and acute pyelonephritis (APN). This was a prospective, open-label, randomized, controlled, multicenter, non-inferiority clinical trial. Patients with cUTI and APN were randomly assigned to a short-course therapy group (intravenous LVFX at750 mg/day for 5 days) or a conventional therapy group (intravenous/oral regimen of LVFX at 500 mg/day for 7-14 days). The clinical, laboratory, and microbiological results were evaluated for efficacy and safety. The median dose of LVFX was 3555.4 mg in the short-course therapy group and 4874.2 mg in the conventional therapy group. Intention-to-treat analysis indicated the clinical effectiveness in the short-course therapy group (89.87%, 142/158) was non-inferior to that in the conventional therapy group (89.31%, 142/159). The microbiological effectiveness rates were also similar (short-course therapy: 89.55%, 60/67; conventional therapy: 86.30%, 63/73; p > 0.05). There were no significant differences in other parameters, including clinical and microbiological recurrence rates. The incidence of adverse effects and drug-related adverse effects were also similar for the short-course therapy group (21.95%, 36/164; 18.90%, 31/164) and the conventional therapy group (23.03%, 38/165; 15.76%, 26/165). Patients with cUTIs and APN who were given short-course LVFX therapy and conventional LVFX therapy had similar outcomes in clinical and microbiological efficacy, tolerance, and safety. The short-course therapy described here is a more convenient alternative to the conventional regimen with potential implication in anti-resistance and cost saving.
[1]Shanghai Jiao Tong Univ, Dept Nephrol, Rui Jin Hosp, Sch Med, 197 Rui Jin Er Rd, Shanghai 200025, Peoples R China.
[2]Shanghai Jiao Tong Univ, Dept Nephrol, Rui Jin Hosp, Sch Med,Pu Dong New Area, 1630 Dong Fang Rd, Shanghai 200127, Peoples R China.
[3]Fudan Univ, Peoples Hosp Shanghai 5, Dept Nephrol, 801 He Qing Rd, Shanghai 200240, Peoples R China.
[4]Beijing Chao Yang Hosp, Dept Infect Dis, 8 Gong Ti South Rd, Beijing 100020, Peoples R China.
[5]Peking Univ, Dept Infect Dis, Hosp 3, 49 Hua Yuan North Rd, Beijing 100191, Peoples R China.
[6]Capital Med Univ, Beijing Anzhen Hosp, Dept Nephrol, 2 An Zhen Rd, Beijing 100029, Peoples R China.
[7]Rocket Force Gen Hosp, Dept Nephrol, 16 Xin Jie Kou Wai St, Beijing 100088, Peoples R China.
[8]Capital Med Univ, Beijing Friendship Hosp, Dept Infect Dis, 95 Yong An Rd, Beijing 100050, Peoples R China.
[9]Zhejiang Univ, Dept Nephrol, Affiliated Hosp 2, Sch Med, 88 Jiefang Rd, Hangzhou 310009, Zhejiang, Peoples R China.
[10]Jiangsu Prov Hosp, Dept Nephrol, 300 Guangzhou Rd, Nanjing 210029, Zhejiang, Peoples R China.
[11]Cent S Univ, Dept Nephrol, Xiangya Hosp 2, 139 Renmin Middle Rd, Changsha 410011, Hunan, Peoples R China.
[12]Daping Hosp, Dept Urol Surg, 10 Changjiang Zhi Rd, Chongqing 400042, Peoples R China.
[13]Shanghai Construct Grp Hosp, Dept Nephrol, 666 Zhongshan North Rd, Shanghai 200083, Peoples R China.
[14]Cent Hosp Yangpu Dist, Dept Nephrol, 450 Tengyue Rd, Shanghai 200090, Peoples R China.
[15]Cent Hosp Minhang Dist, Dept Nephrol, 170 Shensong Rd, Shanghai 201199, Peoples R China.
[16]Lihuili Hosp, Dept Nephrol, Ningbo Med Treatment Ctr, 57 Xingning Rd, Ningbo 315040, Zhejiang, Peoples R China.
(8.0+极速模式)